Markets:

Overview

News

Currencies

International

Treasuries

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

1.490 -0.140 (-8.59%)

Streaming Delayed Price Updated: 1:03 PM EDT, Aug 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alzamend Neuro, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

September 29, 2022

From Alzamend Neuro, Inc.

Via Business Wire

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗

September 28, 2022

Via Benzinga

Alzamend Neuro Receives Positive FDA Response For Its Depression Candidate ↗

July 18, 2022

Via Benzinga

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

September 22, 2022

From Alzamend Neuro, Inc.

Via Business Wire

Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry? ↗

August 09, 2022

According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028.

Via Benzinga

Alzamend Neuro Stock Pops After Benzinga Exclusive On Cognition Therapeutics Alzheimer's Data ↗

August 04, 2022

Shares of biopharmaceutical company Alzamend Neuro Inc (NASDAQ: ALZN) are soaring Thursday afternoon after Cognition Therapeutics Inc (NASDAQ: CGTX) shares surged following the presentation of a...

Via Benzinga

6 Penny Stocks With 1,000% Upside Potential ↗

July 24, 2022

Each of these penny stocks with 1,000% upside potential could rise 10X in the future for investors with a high risk tolerance.

Via InvestorPlace

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

July 18, 2022

From Alzamend Neuro, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 22, 2022

Via Benzinga

Alzamend Neuro to Present at the 12th Annual LD Micro Invitational

June 03, 2022

From Alzamend Neuro, Inc.

Via Business Wire

4 Stocks Under $1 Insiders Are Aggressively Buying ↗

May 27, 2022

The Nasdaq Composite jumped over 300 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...

Via Benzinga

Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

May 17, 2022

From Alzamend Neuro, Inc.

Via Business Wire

Executives Buy Around $5M Of 4 Penny Stocks ↗

May 09, 2022

US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the...

Via Benzinga

18 Stocks Moving in Tuesday's Pre-Market Session ↗

April 26, 2022

Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:...

Via Benzinga

Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

May 05, 2022

From Alzamend Neuro, Inc.

Via Business Wire

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

April 28, 2022

From Alzamend Neuro, Inc.

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

April 13, 2022

Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

April 28, 2022

From BitNile Holdings, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 12, 2022

Gainers

Via Benzinga

Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s

April 11, 2022

From Alzamend Neuro, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 22, 2022

Gainers Palisade Bio (NASDAQ:PALI) shares rose 34.1% to $1.08 during Tuesday's regular session. Trading volume for this security as of 13:31 EST is 52.4 million, which...

Via Benzinga

Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

April 04, 2022

From Alzamend Neuro, Inc.

Via Business Wire

43 Stocks Moving In Tuesday's Mid-Day Session ↗

March 22, 2022

Gainers Forge Global Holdings Inc. (NYSE: FRGE) shares jumped 67.7% to $16.95. True Global Ventures’ portfolio company Forge Global Holdings completed its business...

Via Benzinga

Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

March 28, 2022

From Alzamend Neuro, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 22, 2022

Gainers Palisade Bio (NASDAQ:PALI) stock rose 59.0% to $1.28 during Tuesday's pre-market session. The company's market cap stands at $23.3 million. As per the news...

Via Benzinga

66 Biggest Movers From Yesterday ↗

March 23, 2022

Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 119.5% to settle at $4.39 on Tuesday after the company announced it signed a $60 million sales agreement. Forge Global...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

March 22, 2022

Grab your cup of coffee, investor! We're starting off the day with a dive into the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

30 Stocks Moving in Tuesday's Pre-Market Session ↗

March 22, 2022

Gainers Smart for Life, Inc. (NASDAQ: SMFL) rose 75.3% to $1.63 in pre-market trading. Smart For Life recently said it is launching various products under the Doctors Scientific...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 25, 2022

Gainers Surgalign Holdings (NASDAQ:SRGA) ...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

All News about Alzamend Neuro, Inc. - Common Stock

Starting at /week.